Suspected Pediatric Influenza Risk-Stratification Algorithm: A Clinical Decision Tool

Patrick D Evers1, Michelle Starr2, Michael J McNeil2

  • 1From the Divisions of Cardiology.

Insights

This study developed the Suspected Pediatric Influenza Risk-Stratification Algorithm (SPIRA) to help clinicians identify children with influenza-like illness who truly need treatment, reducing unnecessary testing and medication.

Area of Science:

  • Pediatric infectious diseases
  • Clinical decision support systems
  • Epidemiology

Background:

  • Influenza poses a significant annual health burden on children.
  • Current guidelines often lead to overtreatment or expensive viral testing for children with influenza-like illness (ILI).
  • A need exists for better tools to differentiate children who require empiric treatment from those who need further testing.

Purpose of the Study:

  • To develop and validate a risk-stratification algorithm for children presenting with ILI.
  • To assist clinicians in determining the likelihood of influenza infection in pediatric patients.
  • To optimize the use of empiric antiviral treatment and viral diagnostic testing.

Main Methods:

  • Retrospective analysis of 818 children with ILI presenting to the emergency department.
  • Review of medical records for symptoms, influenza risk factors, and viral assay results.
  • Classification and regression tree analyses were conducted separately for children younger and older than 2 years.

Main Results:

  • For children <2 years, influenza likelihood was associated with influenza-positive contact, lack of immunization, and high-incidence periods.
  • For children ≥2 years, high-risk factors included lack of immunization, high-incidence periods, myalgia, and absence of diarrhea.
  • Specific factors identified low risk for influenza in younger children (immunization, low-incidence season, absence of cough).

Conclusions:

  • The Suspected Pediatric Influenza Risk-Stratification Algorithm (SPIRA) was developed based on these findings.
  • SPIRA can guide clinicians in deciding between empiric treatment and viral testing for children with ILI.
  • The algorithm aims to reduce unnecessary antiviral exposure and costly diagnostic procedures.
Abstract

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
400
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
52
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
332
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
377
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.3K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
502